ExpressPoints
Exploring the Abundance of Biomarkers in Lung Cancer: Current Applications and Future Prospects for Precision Medicine

Download this short summary slideset of key takeaways from a live CCO Webinar on recent advances in biomarkers guiding optimal use of targeted therapy and immunotherapy in the treatment of advanced NSCLC.
Stephen V. Liu, MD
Suresh S. Ramalingam, MD, FACP, FASCO
Lecia V. Sequist, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 2.07 MB
Released: July 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Turning Point Therapeutics Inc.

Related Content

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Results from phase III ATLANTIS trial of lurbinectedin plus doxorubicin in patients with relapsed small-cell lung cancer (SCLC), from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021

CheckMate 9LA analysis of nivolumab plus ipilimumab plus chemotherapy in advanced NSCLC with brain metastases, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue